HDAC9 and neoplasm: Low-dose HDAC inhibitors, for instance, can reprogram tumor-associated macrophages (TAMs) toward an M1-like, pro-inflammatory phenotype with anti-tumor activity, while simultaneously reducing the recruitment of myeloid-derived suppressor cells (MDSCs) into tumors.